Research Paper Volume 14, Issue 19 pp 8077—8094

Novel small molecular compound 2JY-OBZ4 alleviates AD pathology in cell models via regulating multiple targets

class="figure-viewer-img"

Figure 5. 2JY-OBZ4 ameliorated human oligomeric Aβ42 induced synaptic loss in mice primary neuron. (A) CCK-8 assay of mice primary neuron incubated with various concentrations of 2JY-OBZ4 (0 nM, 125 nM, 250 nM, 500 nM, 1μM, 2 μM, 4 μM, 8 μM, 16 μM, 32 μM, 64 μM, 128 μM) for 24 h. n = 3 per group. p value significance is calculated from a one-way ANOVA, data are represented as mean ± SEM. *p < 0.05, compared to controls. (B) Western blots and (C, D) quantitative analysis for synaptophysin and PSD95 in mice primary neuron. MW Molecular weight. n = 3 per group. #p < 0.05 compared to controls, *p < 0.01, **p < 0.01, ****p < 0.0001 compared to the group pretreated with Aβ and treated with DMSO (EJ) Immunofluorescence staining was used to measure the expression of synaptophysin and Map2 in primary neuron (scale bar: 50 μm). (K, L) Quantitative analysis of fluorescence intensity. n = 4 per group. p value significance is calculated from a one-way ANOVA, data are represented as mean ± SEM. #p < 0.05, #### p < 0.0001 compared to controls, *p < 0.01, ***p< 0.001 compared to the group pretreated with Aβ and treated with DMSO.